Added to YB: 2025-10-29
Pitch date: 2025-10-27
NTLA [bearish]
Intellia Therapeutics, Inc.
+38.95%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
Market Cap
$1.0B
Pitch Price
$14.78
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.03
P/E
-2.05
EV/Sales
7.58
Sector
Biotechnology
Category
N/A
Show full summary:
Intellia Therapeutics (NTLA): Severe Safety Red Flags Render Pipeline and Valuation Unsustainable
NTLA short: Lead HAE & ATTR programs hit Hy's law w/ G4 liver events + elevated bilirubin - programs should stop as diseases have safe alternatives. Risk/benefit unacceptable, could kill patients. ~$4.66/share cash value, no advanced replacements. Up 120% since June despite negative data.
Read full article (1 min)